1 / 23

The ‘Lazarus’ Group - increasing joint faith based advocacy on access to medicines

The ‘Lazarus’ Group - increasing joint faith based advocacy on access to medicines. …..for the saving of many lives!.

urit
Download Presentation

The ‘Lazarus’ Group - increasing joint faith based advocacy on access to medicines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The ‘Lazarus’ Group- increasing joint faith based advocacy on access to medicines …..for the saving of many lives!

  2. “Through its impacts on the labour force, households and enterprises, AIDS has played a more significant role in the reversal of human development than any other single factor.” The importance of treatment Personal - lifesaving Generational Relational – stigma reducing Reduces Orphan crisis Economic – local, national Preventative

  3. “A crude scale up to a global level would indicate the global numbers in need of treatment will be in the region of 55 million people by 2030.”

  4. Celebrate saving of life! Vision: Zero new infections, zero discrimination, Zero AIDS-related deaths Revolutionise HIV prevention Catalyse the next phase of treatment, care & support Advance human rights & gender equality for HIV response

  5. HIV Strategy Group • Access to medicines workshop • Own consultation with Pharma Group • Geneva ‘induction’ • Issues to focus on • Updates on MPP, FTA &Treatment 2.0 • Short & long term actions • Group membership • Group name • Mass Campaign idea

  6. Pharma Issues (1) • Innovative new medicine • 20 years patent life • 12 years development (phases 1-3 & 4) • 1 in 100 molecules = ‘success’ • Costs R&D c. $500m • Pharma goals/motives • Shareholder/profit driven • Profits regulated? • Generic versions after 20 years

  7. Impact of Generic Competition

  8. Basic Treatment Model >80% of 5.2m are generic medicines Excludes using treatment as part of prevention

  9. Pressure is building! Patent Barriers Resistance to first line drugs Need/demand for ARVs Supply/Demand Gap Side Effects Treatment 2.0 including Treatment as Prevention Resources for ARVs

  10. Pharma Issues (2) • WTO • TRIPS = Trade related Intellectual Property Rights • India complied in 2005 • But still more difficult for pharma • LDC – 2016 • Voluntary & Compulsory licenses • TRIPS + • Bilateral Trade Agreements • Data exclusivity

  11. MPP – how it will work? Medicines Patent Pool ‘Rights holders’ Pharma Biotech Research labs Generics companies Royalties

  12. Workshop - Informal feedback • Broad group – good participation in Exercise • Comments – “Pitched at right level” • Focus issues list - growing • Potential group members? • (Could have been longer, non competitive?)

  13. Personal Consultation • Discussions/email with existing members • Some strong commitments • Concern group is german centric • Geneva visit • EAA induction • Credibility of breadth of alliance • MSF • Real technical expertise • MPP • Need help with as much campaign/pressure as possible • Caritas • Strong experience – ‘Prescription for Life/HAART’

  14. Medicines Patent Pool • Needs • Single compounds • Fixed dose combinations • Paediatric formulations • Example • Rilpivirine (Tibotek, J&J) – TMC278 • Low manufacturing cost X10 v efavirenz • Better drug in FDCs • Status • Already in • NIH • In negotiation • Gilead, Sequoia, ViiV, and Roche (preparing), • Not yet • Tibotek, Merck, BMS, Abbot

  15. Treatment 2.0 • Jan 2011 New York • Planning meeting • 5 pillars • Community Mobilisation • 3 Regional Consultations

  16. Bilateral FTAs • E.g. EU-India – Current • Data Exclusivity threat • UK Government Minister – Department for Business Innovation and Skills • Dr Vince Cable • Formal response: “We will continue to argue within Europe that the IP provisions in this FTA should not impact negatively on public health in developing countries, including India itself” • Conclusion April --- June ? • South Africa – EU EPA – potential data exclusivity?

  17. Pharma Group ConsultationPotential focus issues? • Medicines Patent Pool • Bilateral trade agreements • Food (Security) • Children – specific formulations • PMTCT – zero vertical transmission • HIV + TB co-infection • Diagnostics • Side effects – stavudine replacement • Palliative care – increasing cancer (morphine) • Mass mobilisation?

  18. Decision making? Passion/Energy of members Size/Importance of Need Opportunity to have impact

  19. Possible Short term Actions(WG teleconference April) • Action: • Pressure Pharmas not yet in MPP • At all levels • Plus dialogue with Generics companies • Bilateral FTA agreements • Investigate: • Inclusion of food/livelihoods training in donor based programmes • Discuss • Other areas • Mass mobilisation idea?

  20. Additional Members • Criteria • Global(south) • Larger members • Expertise & passion • Expressions of Interest • Stuart Keen (World Vision) • Aginel Chingwaro (UEM) – Papua • Winnie Sseruma (Christian Aid) • Ray Sweety Prem Kumar (India, IT) • Additional Needs (members or advisors) • Doctor, Paediatrician, Pharmacist (MSF?)

  21. Group Name • Pharma Working Group • Access to Medicines? • (Essential?) • Access to Treatment? • Treatment 2.0

  22. Mass mobilisation Campaigns e.g. Caritas and EAA

  23. One idea • Promoted by Joseph story • Hear the voices of beneficiaries • Collective Ecumenical approach • Focus on access issues for children • Build on ‘Prescription for Life’ • Ambitious target; • E.g.1m people by WAD 2012 • Utilise mobile phones to register ‘action’ • Promote through churches – member organisations • Partnership with mobile airtime supplier

More Related